| [1] |
Gotlib J. JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside[J]. Hematology Am Soc Hematol Educ Program, 2013, 2013: 529-37.
|
| [2] |
Sliver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis[J]. Expert Rev Hematol, 2013, 6(1): 49-58.
|
| [3] |
Tefferi A. Annual clinical updates in hematological malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia:2011 update on diagnosis, riskstratification, and management[J]. Am J Hematol, 2011, 86(3): 29 2-301.
|
| [4] |
Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis[J]. Curr Hematol Malig Rep, 2009, 4(1): 33-40.
|
| [5] |
Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera[J]. J Clin Oncol, 2009, 27(32): 5418-24.
|
| [6] |
Spanoudakis E, Bazdiara I, Pantelidou D, et al. Dynamics of telomere’s length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms[J]. Leuk Res, 20 11, 35(4): 459-64.
|
| [7] |
Zhu YF, He YK. Mechanisms of the actions of interferons[J]. Zhonghua Gan Zang Bing Za Zhi, 2007, 15(11): 845-6. [朱幼芙, 贺玉凯.干扰素的作用机制[J]. 中华肝脏病杂志, 2007, 15(11): 84 5-6.]
|
| [8] |
Tefferi A. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices[J]. Leuk Lymphoma, 2010, 51(4): 576-82.
|
| [9] |
Silver RT, Vandris K,Wang YL, et al. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy[J]. Leuk Res, 2011, 35(2): 17 7-82.
|
| [10] |
Hasan S, Lacout C, Marty C, et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα[J]. Blood, 2013, 12 2(8): 1464-77.
|
| [11] |
Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferonalfa- 2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera[J]. Blood, 2008, 112(8): 30 65-72.
|
| [12] |
Larsen TS, Møller MB, de Stricker K, et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission[J]. Hematology, 2009, 14(6): 33 1-4.
|
| [13] |
Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2[J]. N Engl J Med, 2013, 369(25): 2391-405.
|
| [14] |
Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms[J]. N Engl J Med, 2013, 369 (25): 2379-90.
|
下载:
